Mylan Pharmaceuticals Private Limited — Trastuzumab Exporter Profile
Indian Pharmaceutical Exporter · #11 for Trastuzumab · $250.0K export value · DGFT Verified
Mylan Pharmaceuticals Private Limited is the #11 Indian exporter of Trastuzumab with $250.0K in export value and 5 verified shipments. Mylan Pharmaceuticals Private Limited holds a 0.3% market share in Trastuzumab exports across 2 countries. The company exports 2 pharmaceutical products worth $900.0K across 1 therapeutic categories.
Mylan Pharmaceuticals Private Limited — Trastuzumab Export Profile: Buyers & Destinations
Where Does India Export Trastuzumab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $11.3M | 225 | 44.3% |
| BRAZIL | $4.1M | 91 | 16.3% |
| TURKEY | $2.7M | 54 | 10.6% |
| UNITED STATES | $1.6M | 33 | 6.5% |
| KENYA | $1.0M | 174 | 4.1% |
| PHILIPPINES | $950.0K | 19 | 3.7% |
| SRI LANKA | $750.0K | 15 | 3.0% |
| VENEZUELA | $650.0K | 13 | 2.6% |
| LEBANON | $600.0K | 12 | 2.4% |
| UKRAINE | $500.0K | 10 | 2.0% |
India exports Trastuzumab to 108 countries. The top destination is NETHERLANDS (44.3%), followed by BRAZIL and TURKEY.
Who Are the Top Buyers of Trastuzumab from India?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN IRELAND LIMITED | NETHERLANDS | $5.4M | 108 |
| MYLAN IRELAND LTD | NETHERLANDS | $3.4M | 68 |
| BIOSIMILAR COLLABORATIONS IRELAND L | NETHERLANDS | $2.1M | 43 |
| ABDI IBRAHIM ILAC SANAYI VE TICARET | TURKEY | $1.1M | 22 |
| BIOCON BIOLOGICS UK LIMITED | BRAZIL | $750.0K | 15 |
| PII OST-WEST EXPRESS | UKRAINE | $500.0K | 10 |
| XXOSIXXLARXXNEWXX LIXXTED | UNITED STATES | $350.0K | 7 |
| ABDI IBRAHIM ILAC SANAYI VE TICARET SANAYIMAH TUNC | TURKEY | $300.0K | 6 |
| ZYDUS PHARMACEUTICALS M?XICO S.A. D | MEXICO | $150.0K | 3 |
| GENERAL FOREIGN TRADE ORGANIZATION | LEBANON | $150.0K | 3 |
India's Trastuzumab is purchased by 329 buyers worldwide. The top buyer is MYLAN IRELAND LIMITED (NETHERLANDS), followed by MYLAN IRELAND LTD and BIOSIMILAR COLLABORATIONS IRELAND L.
What Is India's Total Trastuzumab Export Value and How Much Does Mylan Pharmaceuticals Private Limited Contribute?
India exported $37.2M worth of Trastuzumab through 1,882 shipments from 179 suppliers to 108 countries, serving 329 buyers globally. Mylan Pharmaceuticals Private Limited contributes $250.0K to this total, accounting for 0.3% of India's Trastuzumab exports.
What Is the Average Shipment Value for Mylan Pharmaceuticals Private Limited's Trastuzumab Exports?
Mylan Pharmaceuticals Private Limited's average Trastuzumab shipment value is $50.0K per consignment, based on 5 shipments totaling $250.0K.
How Does Mylan Pharmaceuticals Private Limited Compare to Other Indian Trastuzumab Exporters?
Mylan Pharmaceuticals Private Limited ranks #11 among 179 Indian Trastuzumab exporters with a 0.3% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($25.1M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($3.8M), ZYDUS LIFESCIENCES LIMITED ($3.4M). Mylan Pharmaceuticals Private Limited processed 5 shipments to 2 destination countries.
Regulatory Requirements: Exporting Trastuzumab to Key Markets
What Mylan Pharmaceuticals Private Limited must comply with to export Trastuzumab to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Mylan Pharmaceuticals Private Limited Compare to Nearest Trastuzumab Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | CHANDRA BHAGAT PHARMA LIMITED | $300.0K | 6 | 1 | $50.0K |
| 12 | CADILA HEALTHCARE LTD | $300.0K | 6 | 4 | $50.0K |
| 11 | MYLAN PHARMACEUTICALS PRIVATE LIMITED ★ | $250.0K | 5 | 2 | $50.0K |
| 6 | MEDWISE OVERSEAS PRIVATE LIMITED | $200.0K | 4 | 3 | $50.0K |
| 8 | SAMEEKSHA PHARMACEUTICALS PRIVATE LIMITED | $200.0K | 4 | 1 | $50.0K |
Mylan Pharmaceuticals Private Limited ranks #11 among 179 Indian Trastuzumab exporters. Average shipment value of $50.0K compared to the market average of $208.0K. The closest competitors by value are CHANDRA BHAGAT PHARMA LIMITED and CADILA HEALTHCARE LTD.
Which Indian Ports Ship Trastuzumab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 379 | 20.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 319 | 17.0% |
| BANGALORE AIR | 254 | 13.5% |
| BANGALORE ACC (INBLR4) | 186 | 9.9% |
| Bombay Air | 99 | 5.3% |
| DELHI AIR | 74 | 3.9% |
| AHEMDABAD AIR ACC (INAMD4) | 62 | 3.3% |
| Bangalore Air | 58 | 3.1% |
What Other Advanced Oncology Products Does Mylan Pharmaceuticals Private Limited Export?
Mylan Pharmaceuticals Private Limited also exports these advanced oncology products. Each links to the detailed product page.
About Mylan Pharmaceuticals Private Limited
Mylan Pharmaceuticals Private Limited exports 2 products worth $900.0K. Beyond Trastuzumab, top products include Bevacizumab. View the complete Mylan Pharmaceuticals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Trastuzumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Trastuzumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Pharmaceuticals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 108+ countries, 329+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Trastuzumab Export Data from Mylan Pharmaceuticals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Pharmaceuticals Private Limited's Trastuzumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Pharmaceuticals Private Limited
Full Company Profile →
2 products · $900.0K total trade · 1 categories
Trastuzumab Stats
Company Overview
Top Products by Mylan Pharmaceuticals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Pharmaceuticals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Trastuzumab. For current shipment-level data, contact TransData Nexus.